Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer

Frontiers in Immunology

Immunology

Maribel Castro¹  Rakhshanda Layeequr Rahman¹  Michael W. Melkus¹  Nicole Remmert¹  Sharda P. Singh²  Flávia Sardela de Miranda³ 

[1] Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States;Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, United States;Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States;Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, United States;Department of Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States;Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States;Department of Immunology and Molecular Microbiology, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States;Breast Center of Excellence, Texas Tech University Health Sciences Center, Lubbock, TX, United States;

关键词: breast cancer;    cryoablation;    abscopal effect;    immune checkpoint inhibitors;    immune response;    drug delivery;   

DOI  :  10.3389/fimmu.2023.1258873

 received in 2023-07-14, accepted in 2023-09-18,  发布年份 2023

来源: Frontiers

【 摘 要 】

Breast cancer is the second most common cancer among women in the United States in which the standard of care treatment is surgery with adjunctive therapy. Cryoablation, which destroys the tumor using extremely cold temperatures while preserving the potential tumor antigens, is a promising alternative to surgical resection. It is less invasive, cosmetically appeasing, cost-effective, and capable of contributing to the abscopal effect – the immune response targeting potential distant metastasis. However, to maximize the immunologic benefit of cryoablation in biologically high-risk breast cancers, combination with therapies that enhance immune activation, such as immune checkpoint inhibitors (ICIs) may be necessary. This mini review describes the fundamentals of cryoablation and treatment with ICIs, as well as discuss the caveats in both strategies and current clinical trials aimed to improve this approach to benefit patients.

【 授权许可】

Unknown   
Copyright © 2023 Sardela de Miranda, Castro, Remmert, Singh, Layeequr Rahman and Melkus